Aging America may revive healthcare stocks after a rough year — discover why long-term trends point to a powerful rebound.

Novo Nordisk NVO -1.23% Get Free Report has outperformed the market over the past 5 years by 1.33% on an annualized basis producing an average annual return of 15.96%. Currently, Novo Nordisk has a ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

If you wish to turn $10,000 into $50,000 by 2035, you’re looking at a 400% gain over a 10-year horizon. In the past decade, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Novo Nordisk A/S (NVO) ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a Strong Buy.

Detailed price information for Mr.Cooper Group Inc (COOP-Q) from The Globe and Mail including charting and trades.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date.

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial results on Monday trading.

Hims & Hers stock fell 35% after Novo Nordisk ended their partnership on Monday. Novo Nordisk stopped the deal because Hims sold a cheaper version of Wegovy.